172 related articles for article (PubMed ID: 23208509)
21. A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors.
Gonzalez A; Broussas M; Beau-Larvor C; Haeuw JF; Boute N; Robert A; Champion T; Beck A; Bailly C; Corvaïa N; Goetsch L
Int J Cancer; 2016 Oct; 139(8):1851-63. PubMed ID: 27144973
[TBL] [Abstract][Full Text] [Related]
22. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
23. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
Troiani T; Napolitano S; Vitagliano D; Morgillo F; Capasso A; Sforza V; Nappi A; Ciardiello D; Ciardiello F; Martinelli E
Clin Cancer Res; 2014 Jul; 20(14):3775-86. PubMed ID: 24812410
[TBL] [Abstract][Full Text] [Related]
24. Novel strategy for a bispecific antibody: induction of dual target internalization and degradation.
Lee JM; Lee SH; Hwang JW; Oh SJ; Kim B; Jung S; Shim SH; Lin PW; Lee SB; Cho MY; Koh YJ; Kim SY; Ahn S; Lee J; Kim KM; Cheong KH; Choi J; Kim KA
Oncogene; 2016 Aug; 35(34):4437-46. PubMed ID: 26853467
[TBL] [Abstract][Full Text] [Related]
25. Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer.
Lai AZ; Durrant M; Zuo D; Ratcliffe CD; Park M
J Biol Chem; 2012 Mar; 287(11):8048-59. PubMed ID: 22262855
[TBL] [Abstract][Full Text] [Related]
26. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
[TBL] [Abstract][Full Text] [Related]
27. Cbl-b regulates the sensitivity of cetuximab through ubiquitin-proteasome system in human gastric cancer cells.
Yu P; Fan Y; Qu X; Zhang J; Song N; Liu J; Liu Y
J BUON; 2016; 21(4):867-873. PubMed ID: 27685907
[TBL] [Abstract][Full Text] [Related]
28. Cetuximab attenuates its cytotoxic and radiosensitizing potential by inducing fibronectin biosynthesis.
Eke I; Storch K; Krause M; Cordes N
Cancer Res; 2013 Oct; 73(19):5869-79. PubMed ID: 23950208
[TBL] [Abstract][Full Text] [Related]
29. Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.
Greenall SA; Gherardi E; Liu Z; Donoghue JF; Vitali AA; Li Q; Murphy R; Iamele L; Scott AM; Johns TG
PLoS One; 2012; 7(4):e34658. PubMed ID: 22511956
[TBL] [Abstract][Full Text] [Related]
30. Cbl-family ubiquitin ligases and their recruitment of CIN85 are largely dispensable for epidermal growth factor receptor endocytosis.
Ahmad G; Mohapatra BC; Schulte NA; Nadeau SA; Luan H; Zutshi N; Tom E; Ortega-Cava C; Tu C; Sanada M; Ogawa S; Toews ML; Band V; Band H
Int J Biochem Cell Biol; 2014 Dec; 57():123-34. PubMed ID: 25449262
[TBL] [Abstract][Full Text] [Related]
31. Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.
Yang Y; Mandiyan S; Robinson BS; McMahon G
Cancer Res; 2016 Oct; 76(19):5788-5797. PubMed ID: 27550450
[TBL] [Abstract][Full Text] [Related]
32. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
33. Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Kong-Beltran M; Seshagiri S; Zha J; Zhu W; Bhawe K; Mendoza N; Holcomb T; Pujara K; Stinson J; Fu L; Severin C; Rangell L; Schwall R; Amler L; Wickramasinghe D; Yauch R
Cancer Res; 2006 Jan; 66(1):283-9. PubMed ID: 16397241
[TBL] [Abstract][Full Text] [Related]
34. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met.
Petrelli A; Gilestro GF; Lanzardo S; Comoglio PM; Migone N; Giordano S
Nature; 2002 Mar; 416(6877):187-90. PubMed ID: 11894096
[TBL] [Abstract][Full Text] [Related]
35. Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
Hultberg A; Morello V; Huyghe L; De Jonge N; Blanchetot C; Hanssens V; De Boeck G; Silence K; Festjens E; Heukers R; Roux B; Lamballe F; Ginestier C; Charafe-Jauffret E; Maina F; Brouckaert P; Saunders M; Thibault A; Dreier T; de Haard H; Michieli P
Cancer Res; 2015 Aug; 75(16):3373-83. PubMed ID: 26141862
[TBL] [Abstract][Full Text] [Related]
36. Acquired Resistance to a MET Antibody
Pollmann SE; Calvert VS; Rao S; Boca SM; Madhavan S; Horak ID; Kjaer A; Petricoin EF; Kragh M; Poulsen TT
Mol Cancer Ther; 2018 Jun; 17(6):1259-1270. PubMed ID: 29545332
[TBL] [Abstract][Full Text] [Related]
37. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.
Wang J; Goetsch L; Tucker L; Zhang Q; Gonzalez A; Vaidya KS; Oleksijew A; Boghaert E; Song M; Sokolova I; Pestova E; Anderson M; Pappano WN; Ansell P; Bhathena A; Naumovski L; Corvaia N; Reilly EB
BMC Cancer; 2016 Feb; 16():105. PubMed ID: 26879245
[TBL] [Abstract][Full Text] [Related]
38. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody.
Pacchiana G; Chiriaco C; Stella MC; Petronzelli F; De Santis R; Galluzzo M; Carminati P; Comoglio PM; Michieli P; Vigna E
J Biol Chem; 2010 Nov; 285(46):36149-57. PubMed ID: 20833723
[TBL] [Abstract][Full Text] [Related]
39. Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
Polzer H; Janke H; Schmid D; Hiddemann W; Spiekermann K
Exp Hematol; 2013 Mar; 41(3):271-80.e4. PubMed ID: 23127761
[TBL] [Abstract][Full Text] [Related]
40. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
